Post-Myocardial Infarction Beta Blockers Do Not Decrease Mortality
Am Fam Physician. 2015 Mar 15;91(6):402a-404.
Does beta-blocker treatment after myocardial infarction reduce mortality?
Although recommended by guidelines and used as a so-called quality indicator of hospital care, the use of beta blockers following myocardial infarction, when combined with optimal acute and chronic treatment, does not provide a further survival benefit. Beta-blocker use reduces subsequent reinfarction and angina symptoms, but these benefits begin to wane within 30 days. Heart failure and cardiogenic shock can occur with treatment, and patients often have trouble continuing treatment. (Level of Evidence = 1a)
These authors assembled randomized trials by searching three databases, including Cochrane CENTRAL, and found 60 trials that enrolled more than 100,000 patients. They separately analyzed studies conducted in the reperfusion era (n = 12), because the large gains in mortality reduction associated with the availability of thrombolytics, stents, and grafts—as well as the routine use of aspirin and statins—may blunt any additional benefit of beta-blocker treatment. Two researchers independently selected studies for inclusion and evaluated them for bias. Although early studies showed a benefit with beta blockers, modern era studies show no additional survival benefit when adding a beta blocker to optimal treatment. Beta blockers reduce reinfarction rates (number needed to treat = 209) and angina symptoms (number needed to treat = 26), but these benefits seemed to be limited to the first 30 days after the initial myocardial infarction. Rates of heart failure and cardiogenic shock are increased (numbers needed to treat to harm = 79 and 90, respectively).
Study design: Meta-analysis (randomized controlled trials)
Funding source: Self-funded or unfunded
Setting: Various (meta-analysis)
Reference: Bangalore S, Makani H, Radford M, et al. Clinical outcomes with ß-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med.. 2014; 127( 10): 939– 953.
POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP,search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, Associate Medical Editor.
A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Nov 15, 2018
Access the latest issue of American Family Physician